Fasting reduces liver fibrosis in a mouse model for chronic cholangiopathies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 10, 2013, Pages 1482-1491

  Sokolović, Aleksandar ^a   van Roomen, Cindy P A A ^a   Ottenhoff, Roelof ^a   Scheij, Saskia ^a   Hiralall, Johan K ^a   Claessen, Nike ^a   Aten, Jan ^a   Oude Elferink, Ronald P J ^a   Groen, Albert K ^b   Sokolović, Milka ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Fasting; Inflammation; Liver fibrosis; Matrix remodeling

Indexed keywords

LIPID; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT DISEASE; CONTROLLED STUDY; DIET RESTRICTION; FOOD DEPRIVATION; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STELLATE CELL;

Α-SMA; 36B4; ACTIN, ALPHA 2, SMOOTH MUSCLE; ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY KI 67; APAF; APOPTOTIC PEPTIDASE ACTIVATING FACTOR 1; BAX; BCL-XL; BCL2-ASSOCIATED X PROTEIN; BCL2-LIKE 1; CHEMOKINE (C-C MOTIF) LIGAND 2; CYCLIN-DEPENDENT KINASE INHIBITOR 1A; EGF-LIKE MODULE CONTAINING, MUCIN-LIKE, HORMONE RECEPTOR-LIKE SEQUENCE 1; F4/80; FASTING; GFAP; GLIAL FIBRILLARY ACIDIC PROTEIN; HPRT; HYPOXANTHINE GUANINE PHOSPHORIBOSYL TRANSFERASE; INFLAMMATION; INTEGRIN ALPHA M; KI67; LIVER FIBROSIS; MAC1; MATRIX REMODELING; MCP1; MFS; MPO; MYELOPEROXIDASE; MYOFIBROBLASTS; P21; PCNA; PLASMINOGEN ACTIVATOR, TISSUE; PLASMINOGEN ACTIVATOR, UROKINASE; PLAT; PLAU; PROLIFERATING CELL NUCLEAR ANTIGEN; RIBOSOMAL PROTEIN, LARGE, P0; TGFΒ1; TIMP; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR, BETA 1;

ANIMALS; BILE; BLOTTING, WESTERN; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FASTING; GALLBLADDER DISEASES; LIPIDS; LIVER CIRRHOSIS; MALE; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

MUS;

EID: 84879351414     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.05.012     Document Type: Article

References (90)

1. Hirschfield G.M., Heathcote E.J., Gershwin M.E. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010, 139:1481-1496.
2. Friedman S.L. Liver fibrosis - from bench to bedside. J. Hepatol. 2003, 38(Suppl. 1):S38-S53.
3. Benyon R.C., Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 2001, 21:373-384.
4. Schuppan D., Ruehl M., Somasundaram R., Hahn E.G. Matrix as a modulator of hepatic fibrogenesis. Semin. Liver Dis. 2001, 21:351-372.
5. Friedman S.L. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 2004, 1:98-105.
6. Pinzani M., Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig. Liver Dis. 2004, 36:231-242.
7. Emery P.W. Metabolic changes in malnutrition. Eye (Lond.) 2005, 19:1029-1034.
8. Wang T., Hung C.C., Randall D.J. The comparative physiology of food deprivation: from feast to famine. Annu. Rev. Physiol. 2006, 68:223-251.
9. Barbieri M., Bonafe M., Franceschi C., Paolisso G. Insulin/IGF-I-signaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E1064-E1071.
10. Dwyer D.S., Horton R.Y., Aamodt E.J. Role of the evolutionarily conserved starvation response in anorexia nervosa. Mol. Psychiatry 2011, 16:595-603.
11. Blagosklonny M.V. How to save Medicare: the anti-aging remedy. Aging (Albany NY) 2012, 4:547-552.
12. Hanssen S.A., Hasselquist D., Folstad I., Erikstad K.E. Costs of immunity: immune responsiveness reduces survival in a vertebrate. Proc. Biol. Sci. 2004, 271:925-930.
13. Houston A.I., McNamara J.M., Barta Z., Klasing K.C. The effect of energy reserves and food availability on optimal immune defence. Proc. Biol. Sci. 2007, 274:2835-2842.
14. Chandra R.K. Nutrition and the immune system: an introduction. Am. J. Clin. Nutr. 1997, 66:460S-463S.
15. Hakvoort T.B., Moerland P.D., Frijters R., Sokolovic A., Labruyere W.T., Vermeulen J.L., Ver Loren van T.E., Breit T.M., Wittink F.R., van Kampen A.H., Verhoeven A.J., Lamers W.H., Sokolovic M. Interorgan coordination of the murine adaptive response to fasting. J. Biol. Chem. 2011, 286:16332-16343.
16. Martin S.A., Douglas A., Houlihan D.F., Secombes C.J. Starvation alters the liver transcriptome of the innate immune response in Atlantic salmon (Salmo salar). BMC Genomics 2010, 11:418.
17. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
18. Anson R.M., Guo Z., de C.R., Iyun T., Rios M., Hagepanos A., Ingram D.K., Lane M.A., Mattson M.P. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6216-6220.
19. Nakamura H., Kouda K., Tokunaga R., Takeuchi H. Suppressive effects on delayed type hypersensitivity by fasting and dietary restriction in ICR mice. Toxicol. Lett. 2004, 146:259-267.
20. Goldani H.A., Matte U.S., Ramos A.R., Costa T.G., Winkelmann L.V., Meurer L., Vieira S.M., Kieling C.O., Silveira T.R. The role of food restriction on CCl4-induced cirrhosis model in rats. Exp. Toxicol. Pathol. 2007, 58:331-337.
21. Seki M., Kasama K., Imai K. Effect of food restriction on hepatotoxicity of carbon tetrachloride in rats. J. Toxicol. Sci. 2000, 25:33-40.
22. Keenan K.P., Laroque P., Ballam G.C., Soper K.A., Dixit R., Mattson B.A., Adams S.P., Coleman J.B. The effects of diet, ad libitum overfeeding, and moderate dietary restriction on the rodent bioassay: the uncontrolled variable in safety assessment. Toxicol. Pathol. 1996, 24:757-768.
23. Mauad T.H., van Nieuwkerk C.M., Dingemans K.P., Smit J.J., Schinkel A.H., Notenboom R.G., van den Bergh Weerman M.A., Verkruisen R.P., Groen A.K., Oude Elferink R.P. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 1994, 145:1237-1245.
24. Fickert P., Fuchsbichler A., Wagner M., Zollner G., Kaser A., Tilg H., Krause R., Lammert F., Langner C., Zatloukal K., Marschall H.U., Denk H., Trauner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004, 127:261-274.
25. -/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 2004, 39:117-128.
26. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
27. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Weiglein A.H., Lammert F., Marschall H.U., Tsybrovskyy O., Zatloukal K., Denk H., Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123:1238-1251.
28. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., Zatloukal K., Liu J., Waalkes M.P., Cover C., Denk H., Hofmann A.F., Jaeschke H., Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
29. -/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J. Hepatol. 2005, 43:1045-1054.
30. Moustafa T., Fickert P., Magnes C., Guelly C., Thueringer A., Frank S., Kratky D., Sattler W., Reicher H., Sinner F., Gumhold J., Silbert D., Fauler G., Hofler G., Lass A., Zechner R., Trauner M. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012, 142:140-151.
31. Jacquemin E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin. Liver Dis. 2001, 21:551-562.
32. van Westrhenen R., de Waart D.R., Akman S., Krediet R.T. Assessment of peritoneal fibrosis by conventional light microscopy and hydroxyproline measurements. Perit. Dial. Int. 2004, 24:290-292.
33. Frijters C.M., Ottenhoff R., van Wijland M.J., Van N.C., Groen A.K., Oude Elferink R.P. Influence of bile salts on hepatic mdr2 P-glycoprotein expression. Adv. Enzym. Regul. 1996, 36:351-363.
34. Carey M.C., Small D.M. The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. J. Clin. Invest. 1978, 61:998-1026.
35. Folch J., lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226:497-509.
36. Bijl N., Sokolovic M., Vrins C., Langeveld M., Moerland P.D., Ottenhoff R., van Roomen C.P., Claessen N., Boot R.G., Aten J., Groen A.K., Aerts J.M., van E.M. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 2009, 50:1431-1441.
37. Sokolovic A., Sokolovic M., Boers W., Elferink R.P., Bosma P.J. Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair 2010, 3:3.
38. Ruijter J.M., Ramakers C., Hoogaars W.M., Karlen Y., Bakker O., van den Hoff M.J., Moorman A.F. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 2009, 37:e45.
39. Ruijter J.M., Pfaffl M.W., Zhao S., Spiess A.N., Boggy G., Blom J., Rutledge R.G., Sisti D., Lievens A., De P.K., Derveaux S., Hellemans J., Vandesompele J. Evaluation of qPCR curve analysis methods for reliable biomarker discovery: bias, resolution, precision, and implications. Methods 2012, 59(1):32-46.
40. Sokolovic M., Sokolovic A., van Roomen C.P., Gruber A., Ottenhoff R., Scheij S., Hakvoort T.B., Lamers W.H., Groen A.K. Unexpected effects of fasting on murine lipid homeostasis - transcriptomic and lipid profiling. J. Hepatol. 2010, 52(5):737-744.
41. Guanabens N., Pares A., Alvarez L., Martinez de Osaba M.J., Monegal A., Peris P., Ballesta A.M., Rodes J. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J. Bone Miner. Res. 1998, 13:731-738.
42. Knauper V., Lopez-Otin C., Smith B., Knight G., Murphy G. Biochemical characterization of human collagenase-3. J. Biol. Chem. 1996, 271:1544-1550.
43. Takahara T., Furui K., Yata Y., Jin B., Zhang L.P., Nambu S., Sato H., Seiki M., Watanabe A. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997, 26:1521-1529.
44. Carotti S., Morini S., Corradini S.G., Burza M.A., Molinaro A., Carpino G., Merli M., De S.A., Muda A.O., Rossi M., Attili A.F., Gaudio E. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl. 2008, 14:806-814.
45. Niki T., De Bleser P.J., Xu G., Van Den Berg K., Wisse E., Geerts A. Comparison of glial fibrillary acidic protein and desmin staining in normal and CCl4-induced fibrotic rat livers. Hepatology 1996, 23:1538-1545.
46. Rodriguez-Juan C., de la Torre P., Garcia-Ruiz I., Diaz-Sanjuan T., Munoz-Yague T., Gomez-Izquierdo E., Solis-Munoz P., Solis-Herruzo J.A. Fibronectin increases survival of rat hepatic stellate cells-a novel profibrogenic mechanism of fibronectin. Cell. Physiol. Biochem. 2009, 24:271-282.
47. Sokolovic M., Sokolovic A., Wehkamp D., Ver Loren van T.E., de Waart D.R., Gilhuijs-Pederson L.A., Nikolsky Y., van Kampen A.H., Hakvoort T.B., Lamers W.H. The transcriptomic signature of fasting murine liver. BMC Genomics 2008, 9:528.
48. Overall C.M., Wrana J.L., Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J. Biol. Chem. 1991, 266:14064-14071.
49. Uchinami H., Seki E., Brenner D.A., D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006, 44:420-429.
50. Lee S.R., Guo S.Z., Scannevin R.H., Magliaro B.C., Rhodes K.J., Wang X., Lo E.H. Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci. Lett. 2007, 417:1-5.
51. Taras D., Blanc J.F., Rullier A., Dugot-Senant N., Laurendeau I., Vidaud M., Rosenbaum J. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J. Hepatol. 2007, 46:69-76.
52. Murphy F.R., Issa R., Zhou X., Ratnarajah S., Nagase H., Arthur M.J., Benyon C., Iredale J.P. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 2002, 277:11069-11076.
53. van Nieuwkerk C.M., Elferink R.P., Groen A.K., Ottenhoff R., Tytgat G.N., Dingemans K.P., van den Bergh Weerman M.A., Offerhaus G.J. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1996, 111:165-171.
54. Smit J.J., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van D.L., Mol C.A., Ottenhoff R., van der Lugt N.M., van Roon M.A. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75:451-462.
55. van Nieuwerk C.M., Groen A.K., Ottenhoff R., van W.M., van den Bergh Weerman M.A., Tytgat G.N., Offerhaus J.J., Oude Elferink R.P. The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J. Hepatol. 1997, 26:138-145.
56. Krausgruber T., Blazek K., Smallie T., Alzabin S., Lockstone H., Sahgal N., Hussell T., Feldmann M., Udalova I.A. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat. Immunol. 2011, 12:231-238.
57. Spanheimer R.G., Peterkofsky B. A specific decrease in collagen synthesis in acutely fasted, vitamin C-supplemented, guinea pigs. J. Biol. Chem. 1985, 260:3955-3962.
58. Spanheimer R., Zlatev T., Umpierrez G., DiGirolamo M. Collagen production in fasted and food-restricted rats: response to duration and severity of food deprivation. J. Nutr. 1991, 121:518-524.
59. Berg R.A., Kerr J.S. Nutritional aspects of collagen metabolism. Annu. Rev. Nutr. 1992, 12:369-390.
60. Friedman S.L. Hepatic fibrosis - overview. Toxicology 2008, 254:120-129.
61. Zaman A.K., French C.J., Schneider D.J., Sobel B.E. A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart. Exp. Biol. Med. (Maywood) 2009, 234:246-254.
62. Bueno M., Salgado S., Beas-Zarate C., Armendariz-Borunda J. Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. J. Gene Med. 2006, 8:1291-1299.
63. Sun C., Li D.G., Chen Y.W., Chen Y.W., Wang B.C., Sun Q.L., Lu H.M. Transplantation of urokinase-type plasminogen activator gene-modified bone marrow-derived liver stem cells reduces liver fibrosis in rats. J. Gene Med. 2008, 10:855-866.
64. Shimizu M., Hara A., Okuno M., Matsuno H., Okada K., Ueshima S., Matsuo O., Niwa M., Akita K., Yamada Y., Yoshimi N., Uematsu T., Kojima S., Friedman S.L., Moriwaki H., Mori H. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology 2001, 33:569-576.
65. Hertig A., Berrou J., Allory Y., Breton L., Commo F., Costa De Beauregard M.A., Carmeliet P., Rondeau E. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J. 2003, 17:1904-1906.
66. Kallis Y.N., Robson A.J., Fallowfield J.A., Thomas H.C., Alison M.R., Wright N.A., Goldin R.D., Iredale J.P., Forbes S.J. Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response. Gut 2011, 60:525-533.
67. Kelly M.D., Styles J.A., Pritchard N.R. Analysis of cytological changes in hepatocytes from rats dosed with 3'-methyl-4-dimethylaminoazobenzene: initial response appears to involve cytokinesis of binucleated cells. Cancer Lett. 1990, 53:1-4.
68. Lu M.H., Warbritton A., Tang N., Bucci T.J. Dietary restriction alters cell proliferation in rats: an immunohistochemical study by labeling proliferating cell nuclear antigen. Mech. Ageing Dev. 2002, 123:391-400.
69. James S.J., Muskhelishvili L. Rates of apoptosis and proliferation vary with caloric intake and may influence incidence of spontaneous hepatoma in C57BL/6×C3H F1 mice. Cancer Res. 1994, 54:5508-5510.
70. Friedman S.L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 2008, 88:125-172.
71. Morini S., Carotti S., Carpino G., Franchitto A., Corradini S.G., Merli M., Gaudio E. GFAP expression in the liver as an early marker of stellate cells activation. Ital. J. Anat. Embryol. 2005, 110:193-207.
72. Lin S., Saxena N.K., Ding X., Stein L.L., Anania F.A. Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol. Endocrinol. 2006, 20:3376-3388.
73. Frederich R.C., Lollmann B., Hamann A., Napolitano-Rosen A., Kahn B.B., Lowell B.B., Flier J.S. Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J. Clin. Invest. 1995, 96:1658-1663.
74. Ahima R.S., Prabakaran D., Mantzoros C., Qu D., Lowell B., Maratos-Flier E., Flier J.S. Role of leptin in the neuroendocrine response to fasting. Nature 1996, 382:250-252.
75. Faggioni R., Moser A., Feingold K.R., Grunfeld C. Reduced leptin levels in starvation increase susceptibility to endotoxic shock. Am. J. Pathol. 2000, 156:1781-1787.
76. Pruett S.B., Fan R., Myers L.P., Wu W.J., Collier S. Quantitative analysis of the neuroendocrine-immune axis: linear modeling of the effects of exogenous corticosterone and restraint stress on lymphocyte subpopulations in the spleen and thymus in female B6C3F1 mice. Brain Behav. Immun. 2000, 14:270-287.
77. Pruett S.B., Fan R. Quantitative modeling of suppression of IgG1, IgG2a, IL-2, and IL-4 responses to antigen in mice treated with exogenous corticosterone or restraint stress. J. Toxicol. Environ. Health A 2001, 62:175-189.
78. Munck A., Guyre P.M., Holbrook N.J. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr. Rev. 1984, 5:25-44.
79. Khansari D.N., Murgo A.J., Faith R.E. Effects of stress on the immune system. Immunol. Today 1990, 11:170-175.
80. Klebanov S., Diais S., Stavinoha W.B., Suh Y., Nelson J.F. Hyperadrenocorticism, attenuated inflammation, and the life-prolonging action of food restriction in mice. J. Gerontol. A Biol. Sci. Med. Sci. 1995, 50:B78-B82.
81. Krenning G., Zeisberg E.M., Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 2010, 225:631-637.
82. Zeisberg E.M., Kalluri R. Origins of cardiac fibroblasts. Circ. Res. 2010, 107:1304-1312.
83. Oviedo-Orta E., Bermudez-Fajardo A., Karanam S., Benbow U., Newby A.C. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008, 124:42-50.
84. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., Wu S., Lang R., Iredale J.P. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 2005, 115:56-65.
85. McClain C.J., Barve S.S., Barve A., Marsano L. Alcoholic liver disease and malnutrition. Alcohol. Clin. Exp. Res. 2011, 35:815-820.
86. Verslype C., Cassiman D. Cirrhosis and malnutrition: assessment and management. Acta Gastroenterol. Belg. 2010, 73:510-513.
87. Harrison S.A., Day C.P. Benefits of lifestyle modification in NAFLD. Gut 2007, 56:1760-1769.
88. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
89. Li Z.Z., Berk M., McIntyre T.M., Feldstein A.E. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem. 2009, 284:5637-5644.
90. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., Bhanot S., Monia B.P., Li Y.X., Diehl A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.